Parkinson's New Treatments 2026 — Research Insights
2026 Parkinson's treatment advances: alpha-synuclein targeting, LRRK2 gene therapy, nicotinamide riboside trials. AI-analyzed with safety scores.
Standard of Care
Levodopa/Carbidopa, dopamine agonists, MAO-B inhibitors, deep brain stimulation — primarily dopamine replacement and symptom control.
Prevalence
~1 million Americans living with Parkinson's. ~90,000 new diagnoses per year.
Research by Therapy Category
- Stem Cell Therapy Research
- Anktiva Immunotherapy Research
- Bioactive Peptide Research
- Gene Therapy & CRISPR Research
- Nutraceutical & Vitamin Research
- Antiparasitic Drug Repurposing Research
- Lifestyle Intervention Research
- Engineered Cell Therapy Research
- Off-Label Drug Repurposing Research
- Microbiome & Mitochondrial Intervention Research
- Diagnostic Test & Biomarker Research
- Computational Chemistry & Molecular Analysis
- Hormonal & Women's Health Research
- Disease Mechanism Education for Patients